A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH3)
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Everolimus; Imatinib; Infliximab; Methotrexate; Mycophenolate mofetil; Pentostatin; Sirolimus
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH3
- Sponsors Incyte Corporation; Novartis; Novartis Pharma A.G.
- 23 Jun 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 Status changed from planning to not yet recruiting.
- 16 Feb 2017 New trial record